MA52812A - Inhibiteurs de sarm1 - Google Patents
Inhibiteurs de sarm1Info
- Publication number
- MA52812A MA52812A MA052812A MA52812A MA52812A MA 52812 A MA52812 A MA 52812A MA 052812 A MA052812 A MA 052812A MA 52812 A MA52812 A MA 52812A MA 52812 A MA52812 A MA 52812A
- Authority
- MA
- Morocco
- Prior art keywords
- sarm1 inhibitors
- sarm1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682054P | 2018-06-07 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52812A true MA52812A (fr) | 2021-04-14 |
Family
ID=68770700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052812A MA52812A (fr) | 2018-06-07 | 2019-06-06 | Inhibiteurs de sarm1 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12624026B2 (fr) |
| EP (1) | EP3801503A4 (fr) |
| JP (1) | JP7481329B2 (fr) |
| CN (2) | CN112867489A (fr) |
| MA (1) | MA52812A (fr) |
| WO (1) | WO2019236890A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| CA3102645A1 (fr) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| CN112955150A (zh) * | 2018-10-19 | 2021-06-11 | 达萨玛治疗公司 | 与nad+或nad+前体组合的sarm1抑制剂 |
| CA3123215C (fr) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs |
| US12624025B2 (en) * | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7319395B2 (ja) | 2019-06-14 | 2023-08-01 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| WO2021050913A1 (fr) | 2019-09-12 | 2021-03-18 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| WO2021108602A1 (fr) * | 2019-11-26 | 2021-06-03 | Disarm Therapeutics, Inc. | Méthodes et compositions pour la neuroprotection |
| EP4083037A4 (fr) * | 2019-12-26 | 2024-01-24 | Yonsei University, University-Industry Foundation(UIF). | Dérivé de pyrrolidine et composition pharmaceutique de prévention ou de traitement de maladies associées à la protéine bêta-amyloïde ou tau contenant ce dernier |
| AU2021206651B2 (en) * | 2020-01-07 | 2024-02-22 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CA3174321A1 (fr) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Derives d'indazole utiles en tant qu'inhibiteurs de sarm1 |
| WO2021207308A1 (fr) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Dérivés de pyrazole condensés utiles en tant qu'inhibiteurs de sarm1 |
| EP4192828A1 (fr) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Dérivés de pyridine substitués utiles comme inhibiteurs de sarm1 |
| TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Ｓａｒｍ１之抑制劑 |
| WO2022060812A1 (fr) * | 2020-09-16 | 2022-03-24 | Nura Bio, Inc. | Dérivés de pyridine substitués utiles comme inhibiteurs de sarm1 |
| CN117797146A (zh) * | 2020-11-12 | 2024-04-02 | 科辉智药生物科技（无锡）有限公司 | Sarm1酶活性抑制剂及其在神经退行性疾病中的应用 |
| CA3200439A1 (fr) * | 2020-12-08 | 2022-06-16 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 a base de benzopyrazole |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
| WO2023193809A1 (fr) * | 2022-04-08 | 2023-10-12 | 深圳众格生物科技有限公司 | Composé inhibiteur de sarm1, composition pharmaceutique le contenant, sa méthode de préparation et ses utilisations |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA847926B (en) | 1983-10-17 | 1986-05-28 | Lilly Co Eli | 3-bicyclicpyridinium-methyl cephalosporins |
| EP0187456A1 (fr) | 1984-11-29 | 1986-07-16 | Ici Pharma | Dérivés de céphalosporine |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| CA2443918C (fr) | 2001-04-11 | 2012-06-05 | Senju Pharmaceutical Co., Ltd. | Agents contenant des inhibiteurs de la kinase rho ameliorant les troubles de la fonction visuelle |
| US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
| US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
| JP2006516603A (ja) | 2003-01-27 | 2006-07-06 | ファイザー・プロダクツ・インク | イソチアゾール誘導体 |
| WO2005082001A2 (fr) | 2004-02-20 | 2005-09-09 | The Scripps Research Institute | Inhibiteurs ameliores de proteine kinase a base d'isothiazole |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US20060217390A1 (en) * | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2006133417A1 (fr) * | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines comme inhibiteurs de mek |
| WO2008118626A2 (fr) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibiteurs de jnk et procédés pour identifier des inhibiteurs de jnk |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US8067452B2 (en) | 2007-06-21 | 2011-11-29 | Valeant Pharmaceuticals International | 3-hydroxyisothiazole-4-carboxamidine derivatives as CHK2 inhibitors |
| US20100324049A1 (en) | 2007-09-27 | 2010-12-23 | Makoto Ando | Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| WO2011019678A1 (fr) | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Isothiozoles pour traiter des affections oculaires |
| CA2780922A1 (fr) | 2010-02-11 | 2011-08-18 | OSI Pharmaceuticals, LLC | Derives de la 7-aminofuropyridine |
| USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| WO2012178022A2 (fr) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Applications thérapeutiques ciblant sarm1 |
| GB201310460D0 (en) | 2013-06-12 | 2013-07-24 | Lytix Biopharma As | Compounds |
| WO2018011628A1 (fr) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
| EP4091622A1 (fr) | 2016-08-16 | 2022-11-23 | Henry Ford Health System | Compositions pour le traitement de la douleur neuropathique induite par la chimiothérapie |
| EP3515426A1 (fr) | 2016-09-24 | 2019-07-31 | Washington University | Inhibiteurs de l'activité sarm1 nadase et utilisations de ceux-ci |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| IL251949A0 (en) * | 2017-04-26 | 2017-07-31 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Small organic molecules for use in the treatment of neuro-inflammatory diseases |
| CA3102645A1 (fr) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| CA3123215C (fr) * | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
-
2019
- 2019-06-06 EP EP19815890.9A patent/EP3801503A4/fr active Pending
- 2019-06-06 CN CN201980052440.2A patent/CN112867489A/zh active Pending
- 2019-06-06 JP JP2021518047A patent/JP7481329B2/ja active Active
- 2019-06-06 MA MA052812A patent/MA52812A/fr unknown
- 2019-06-06 WO PCT/US2019/035846 patent/WO2019236890A1/fr not_active Ceased
- 2019-06-06 US US16/972,670 patent/US12624026B2/en active Active
- 2019-06-06 CN CN202510537996.8A patent/CN120398784A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801503A1 (fr) | 2021-04-14 |
| JP2021527126A (ja) | 2021-10-11 |
| CN120398784A (zh) | 2025-08-01 |
| CA3108669A1 (fr) | 2019-12-12 |
| CN112867489A (zh) | 2021-05-28 |
| EP3801503A4 (fr) | 2021-12-08 |
| WO2019236890A1 (fr) | 2019-12-12 |
| US20210261537A1 (en) | 2021-08-26 |
| JP7481329B2 (ja) | 2024-05-10 |
| US12624026B2 (en) | 2026-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| EP4007756C0 (fr) | Inhibiteurs de kif18a | |
| IL269196A (en) | Novel inhibitors | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| MA53287A (fr) | Inhibiteurs de prmt5 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3788042A4 (fr) | Inhibiteurs de bcl-2 | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| EP3801499A4 (fr) | Inhibiteurs de sarm1 | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| MA52635A (fr) | Inhibiteurs de magl | |
| EP3980011C0 (fr) | Inhibiteurs de sarm1 | |
| EP3787635A4 (fr) | Inhibiteurs de cd73 | |
| EP3856176A4 (fr) | Inhibiteurs de vap-1 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3773537A4 (fr) | Inhibiteurs de stat3 | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3856194A4 (fr) | Inhibiteurs de vap-1 |